Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.
Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.
Address: Top Floor, 111 Rathmines Road Lr, Dublin 6
Tel: 353 (01) 441 0024
GreenCross Publishing is owned by Graham Cooke.
The European Medicines Agency (EMA) has issued a public health statement highlighting serious side effects associated with the drugs chloroquine and hydroxychloroquine
The medicines are being used to treat patients with Covid-19 and investigated in clinical trials.
But recent studies have shown “serious, in some cases fatal, heart rhythm problems with chloroquine and hydroxychloroquine, particularly when taken at high doses or in combination with the antibiotic azithromycin”, according to the EMA.
In Ireland, the HSE on 30 March issued advice to pharmacy contractors regarding conservation of the drug hydroxychloroquine.
The medication is used for the treatment of rheumatoid and lupus conditions, but has been shown to have some antiviral activity against Covid-19.
Because of efforts to preserve stock of the medication for hospital patients with the virus, Prof Michael Barry, National Clinical Lead, HSE Medicines Management asked prescribers to consider alternatives when prescribing the drug for patients in the community with rheumatoid and lupus conditions.
On 14 April, further guidance was issued by the HSE to GPs and pharmacists regarding azithromycin.
It advised that prescriptions for azithromycin should not be offered in the community for the management of patients with Covid-19 in the home, as part of efforts to maintain supplies of the drug here.
The EMA has advised healthcare professionals to “closely monitor patients with Covid-19 receiving chloroquine or hydroxychloroquine and to take into account pre-existing heart problems that can make patients more prone to heart rhythm issues”.
“They [healthcare professionals] should carefully consider the possibility of side-effects, particularly with higher doses, and exercise extra caution when combining treatment with other medicines such as azithromycin that may cause similar side effects on the heart. Patients and healthcare professionals are reminded to report any suspected side-effects to their national regulatory authorities.”
ENDS
A strategy and implementation plan for genomics in Ireland “will be developed and published before the...
Consultant-led virtual Fracture Assessment Clinics (vFAC), commonly used to manage fractures in patients, is improving outcomes...
The ICGP is examining alternative pathways for entry into general practice training as part of efforts...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
Leave a Reply
You must be logged in to post a comment.